ADAMTS13 and thrombotic thrombocytopenic purpura: Severe deficiency of plasma ADAMTS-13 activity, primarily resulting from acquired autoantibodies against ADAMTS-13, may lead to a potentially fatal syndrome thrombotic thrombocytopenic purpura (TTP) [11,12].